Gilead Sciences is close to a pharma licensing deal with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan. Read the full story
Gilead Sciences is close to a pharma licensing deal with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan. Read the full story
OraSure Technologies has entered into biotech deal and Co-Promotion Agreement with AbbVie under which AbbVie and OraSure will co-promote the Company's OraQuick HCV Rapid Test in the United States. Read the full story
Vertex Pharmaceuticals is a global biotechnology company creating new possibilities in medicines, specifically for the diseases hepatitis C and Cystic Fibrosis. Read the full story
Vertex has announced only 1 M&A deal since 2009, with the acquisition of ViroChem. Read the full story
Vertex Pharmaceuticals, a biotechnology company founded in 1989 and headquartered in Massachusetts has rapidly risen as one of the leading biotechnology companies in the world. Read the full story